Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma

Ou, Ming Ching; Liu, Y.-S.; Chuang, Ming Tsung; Huang, Lanshan; Lin, Chun–Shu

doi:10.1016/j.crad.2018.12.008

Cited by 6 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By contrast, in HCC with a smooth tumor margin, D-TACE-HAIC and DEB-TACE led to a similar median OS (37.0 vs 35.0 months), consistent with the median OS of 33.4–35.6 months for large non-infiltrative HCC undergoing DEB-TACE in previous studies. 10 , 11 In our study, patients with a smooth tumor margin had a high proportion (72.7% [24/33]) of cases with tumor size of 5.1–10 cm, and a similar ORR was achieved in the two groups (82.4% vs 87.5%). These results indicated that, for patients with a smooth tumor margin and tumor size of 5.1–10 cm, DEB-TACE alone might achieve an excellent efficacy and combining HAIC may not benefit.…”

Section: Discussionsupporting

confidence: 56%

“… 4 , 5 Different from c-TACE, TACE using drug-eluting beads (DEB-TACE) can increase the intensity and duration of tumor ischemic necrosis and deliver large amounts of chemotherapeutics to the tumor in a controlled and sustained manner. 6 , 7 For large or huge HCC, DEB-TACE may lead to higher ORR 3 , 8 , 9 and longer time to progression 8 , 10 with an improved tolerability 9 , 11 when compared with c-TACE.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma

Huang¹,

Huang²,

Zhan³

et al. 2021

JHC

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 56%

Section: Introductionmentioning

confidence: 99%

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma

Huang¹,

Huang²,

Zhan³

et al. 2021

JHC

View full text Add to dashboard Cite

“…Longer TTP has been reported in previous retrospective studies [18,19]. In particular, in a series of 63 consecutive patients, Ou et al showed a significantly longer TTP in the first 2 years following DEB-TACE compared to lipiodol-TACE (HR = 0.51, 95% CI: 0.29-0.88; p = 0.009) [18]. However, no data have been specifically reported for patients achieving CR early after treatment.…”

Section: Discussionmentioning

confidence: 89%

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis

Bargellini¹,

Lorenzoni

Lorenzoni³

et al. 2021

Eur Radiol

View full text Add to dashboard Cite

Objectives To retrospectively compare long-term outcomes of first-line drug-eluting particle (DEB)- transarterial chemoembolization (TACE) and lipiodol-TACE, in patients with unresectable hepatocellular (HCC). Methods We retrospectively reviewed our database to identify adult patients with treatment-naïve unresectable HCC, who underwent TACE from 2006 to 2013. Patients were excluded in the absence of complete medical records relative to first TACE, 1-month follow-up, and/or sufficient follow-up data. Periprocedural complications, duration of hospitalization, 1-month tumor response by mRECIST, time to tumor progression (TTP) and target tumor progression (TTTP), and overall survival (OS) were evaluated. Results Out of an initial series of 656 patients, 329 patients were excluded for unavailability of sufficient baseline and/or follow-up data. The remaining 327 patients underwent either lipiodol-TACE (n = 160) or DEB-TACE (n = 167). Patients treated with lipiodol-TACE had a significantly higher tumor burden. By propensity score, patients were matched according to baseline differences (BCLC stage, uninodular or multinodular HCC, and unilobar or bilobar HCC), resulting in 101 patients in each treatment group. Lipiodol-TACE was associated with a significantly higher incidence of adverse events (p = 0.03), and longer hospitalization (mean, 2.5 days vs 1.9 days; p = 0.03), while tumor response, TTP, and OS were comparable. In patients achieving 1-month complete response (CR) of target tumor, TTTP was significantly (p = 0.009) longer after DEB-TACE compared to lipiodol-TACE (median, 835 vs 353 days), resulting in a lower number of re-treatments during the entire follow-up (0.75 vs 1.6, p = 0.01). Conclusion Compared to lipiodol-TACE, DEB-TACE offers higher tolerability, reduced hospitalization, and more durable target tumor response after CR. Key Points • Compared to lipiodol-TACE, DEB-TACE is better tolerated and has reduced side effects, which translates into shorter hospitalization. • When complete radiological response according to the mRECIST is obtained 1 month after the procedure, DEB-TACE offers a more durable local tumor control compared to lipiodol-TACE. • In these patients, the longer duration of response after DEB-TACE translates into a lower number of re-interventions.

show abstract

“…6,8 Drug-eluting bead (DC Bead, Boston Scientific, Massachusetts, USA) with doxorubicin (DEBDOX) represents the second generation of TACE where the liquid embolic agent is substituted with size calibrated hydrogel microsphere beads ranging from 70 to 700 µm that are biocompatible, hydrophilic, non-resorbable, and capable of loading chemotherapeutic agent, most commonly with doxorubicin in Taiwan. [9][10][11] The landmark PRECISION V, multicenter randomized controlled trial (RCT) demonstrated that tumor response for DEBDOX-TACE significantly outperformed cTACE in the Eastern Cooperative Oncology Group (ECOG) 1, Child-Pugh B, bilobar, and recurrent disease subgroups. DEBDOX-TACE demonstrated a better safety profile with a significant decrease in serious liver-related adverse events and systemic side effects versus cTACE.…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)

Liu¹,

Chang²,

Liang³

et al. 2022

JHC

View full text Add to dashboard Cite

Purpose The aim of this retrospective study was to evaluate the safety and efficacy of patients with hepatocellular carcinoma treated with drug-eluting bead with doxorubicin transarterial chemoembolization (DEBDOX-TACE) in Taiwan. Patients and Methods We retrospectively investigated 630 hepatocellular carcinoma patients who underwent DEBDOX-TACE in multiple institutions from 2011 to 2016 in Taiwan. Tumor response was assessed per modified response evaluation criteria in solid tumors, overall survival, and safety. Results This study included 630 patients who underwent DEBDOX-TACE, participants’ mean age was 66 years, 68.1% males and 15.6% females. The mean doxorubicin dose administered via DEBDOX-TACE was 56 mg. Complete and partial response rates were 14.6% and 49.2%, respectively, with a disease control rate of 84.6%. The median overall survival was 29.2 months. The most common post-embolization symptom was abdominal pain (22.4%). No hepatic encephalopathy and no procedure-related death were found. Conclusion Real-world data from Taiwan demonstrated that DEBDOX-TACE for hepatocellular carcinoma can achieve high tumor response rate with low adverse events.

show abstract

Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma

Cited by 6 publications

References 31 publications

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis

Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)

Contact Info

Product

Resources

About